Revenue fell 73% and net profit turned negative amid weak vaccine demand, but R&D investment grew and cash flow improved. The company remains focused on innovation and risk control to navigate industry headwinds.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.